

Impax, the investment manager focused on environmental sector, saw its assets under management rise by 40% in the six months to March 31 as markets im...


Cobham trades on a surprisingly thin multiple of 11.6 times Evolution's forecasts for 2010. That falls to 10.8 times on the numbers for 2011, suggesti...


TechMARK is dominated by pharma companies who have disappointed the market in the past week. Antisoma and Vernalis continue their declines. Shares i...


Disappointing results from the IN-STEP Phase IIb study for the safety and efficacy of V3381 (indantadol) hit the Vernalis share price. The study was...


Engineering design software provider Aveva is rising on the back of yesterday's upgrade by broker Panmure Gordon. The broker has not touched the for...


Pharma company Vernalis will receive a $3m milestone payment from Novartis following the commencement of a phase II study of one of its cancer drugs. ...


Malcolm Calvert, formerly a partner at blue-blooded stockbroker Cazenove, has been sentenced to 21 months in jail for insider dealing offences. The 6...


Shares in electronic components supplier e2v Technologies perked up following last Friday's announcement that its chairman had increased his stake in ...